BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 3722962)

  • 21. Comparative study of short term results in two multidrug regimens in multibacillary leprosy.
    Singh RP; Tiwari VD; Chattopadhyay SP
    Indian J Lepr; 1993; 65(2):173-80. PubMed ID: 8345231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serious side effects of rifampin on the course of WHO/MDT: a case report.
    Namisato M; Ogawa H
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):277-82. PubMed ID: 11221090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of combined treatments comprising 6 months' administration of rifampicin in multibacillary leprosy].
    Pattyn SR; Husser JA; Saint-André P
    Acta Leprol; 1986; 4(4):445-6. PubMed ID: 3296614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A trial of polychemotherapy of leprosy in the Dakar region. Initial observations on the acceptability of the protocols used].
    Millan J; Bodian M; Naudin JC; Diouf B; Boucher P; Ndoye B; Grosset J
    Acta Leprol; 1986; 4(1):19-35. PubMed ID: 3526792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
    Rodríguez G; Pinto R; López F; Gómez Y
    Biomedica; 2009 Mar; 29(1):18-24. PubMed ID: 19753835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug therapy in leprosy.
    Manglani PR; Arif MA
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
    Ravanes JM; Cellona RV; Balagon M; Abalos RM; Walsh GP; Walsh DS
    Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):323-30. PubMed ID: 21710853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of two multidrug regimen in hospitalised multibacillary cases.
    Chattopadhyay SP; Gupta CM; Bhate RD; Bhate RP; Sreevatsa
    Indian J Lepr; 1989 Apr; 61(2):196-205. PubMed ID: 2746028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy of leprosy.
    Biswas SK;
    J Indian Med Assoc; 2004 Dec; 102(12):695-6, 698. PubMed ID: 15871354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug therapy regimen for leprosy.
    Firooz A
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
    Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
    Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
    Ji B; Perani EG; Petinom C; Grosset JH
    Antimicrob Agents Chemother; 1996 Feb; 40(2):393-9. PubMed ID: 8834886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paucibacillary leprosy: a comparative study of different schedules of multidrug therapy.
    Ramakrishnan KR; Arora PN; Aggarwal SK; Ramachandra S
    Indian J Lepr; 1988 Oct; 60(4):542-8. PubMed ID: 3253333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clofazimine: new products. Major antileprous drug.
    Prescrire Int; 1999 Apr; 8(40):44-6. PubMed ID: 10848059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.